share_log

榮昌生物：海外監管公告 - 關於部分募投項目結項並將節餘募集資金永久補充流動資金的公告

REMEGEN: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

Hong Kong Stock Exchange ·  Apr 26 08:50
Summary by Moomoo AI
荣昌生物於2024年4月26日宣布，其「生物新药产业化项目」已结项，并将节余募集资金1,114.71万元永久补充流动资金。此举旨在提高募集资金使用效率，满足公司经营发展需要。荣昌生物此前于2022年3月31日首次公开发行普通股，募集资金总额达人民币26.12亿元，扣除发行费用后净额为人民币25.05亿元。独立董事及监事会均同意此次募投项目结项及资金使用计划，认为符合公司及股东利益，不会对公司生产经营造成重大影响。保荐机构华泰联合证券对此亦出具了明确同意的核查意见。
荣昌生物於2024年4月26日宣布，其「生物新药产业化项目」已结项，并将节余募集资金1,114.71万元永久补充流动资金。此举旨在提高募集资金使用效率，满足公司经营发展需要。荣昌生物此前于2022年3月31日首次公开发行普通股，募集资金总额达人民币26.12亿元，扣除发行费用后净额为人民币25.05亿元。独立董事及监事会均同意此次募投项目结项及资金使用计划，认为符合公司及股东利益，不会对公司生产经营造成重大影响。保荐机构华泰联合证券对此亦出具了明确同意的核查意见。
RONG CHANG BIO ANNOUNCED ON APRIL 26, 2024 THAT ITS “BIOPHARMACEUTICAL INDUSTRIALIZATION PROJECT” HAS BEEN COMPLETED AND THAT IT WILL RAISE THE REMAINING FUNDS RAISED AT $1,114.71 MILLION TO PERMANENTLY REPLENISH LIQUID FUNDS. This is aimed at improving the efficiency of the use of raising funds to meet the company's operational development needs. Prior to its initial public offering of ordinary shares on March 31, 2022, Rong Cheong Bios raised the total amount of RMB26.12, net post-issue fee of RMB25.05. The Independent Directors and the Board of Directors agree that this investment project and the fund use plan are in the best interests of the Company and its shareholders and will not have a material impact on the Company's production operations. The advisory body, Huatai United Securities, also expressly consented to this.
RONG CHANG BIO ANNOUNCED ON APRIL 26, 2024 THAT ITS “BIOPHARMACEUTICAL INDUSTRIALIZATION PROJECT” HAS BEEN COMPLETED AND THAT IT WILL RAISE THE REMAINING FUNDS RAISED AT $1,114.71 MILLION TO PERMANENTLY REPLENISH LIQUID FUNDS. This is aimed at improving the efficiency of the use of raising funds to meet the company's operational development needs. Prior to its initial public offering of ordinary shares on March 31, 2022, Rong Cheong Bios raised the total amount of RMB26.12, net post-issue fee of RMB25.05. The Independent Directors and the Board of Directors agree that this investment project and the fund use plan are in the best interests of the Company and its shareholders and will not have a material impact on the Company's production operations. The advisory body, Huatai United Securities, also expressly consented to this.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more